BRAF and melanoma: Similarly, in syngeneic mouse models of BRAF V600E-mutated melanoma, PLX-3397 combination therapy with adoptive cell transfer immunotherapy, showed reduction in TAMs and increase in tumor infiltrating lymphocytes leading to increased release of IFN-γ [80].